Drug intelligence / Profile preview

HAC2-431

Development stage: Unknown
Lead developer: Huons
Modality: Small Molecules

Overview

HAC2-431 is a small molecule therapeutic candidate being developed by Huons for the treatment of hypercholesterolemia. Currently in Phase 1 clinical trials, it is classified as either a New Chemical Entity (NCE) or an Incrementally Modified Drug (IMD) within the company's metabolic disease pipeline. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is intended to manage lipid levels in patients with high cholesterol.

Beyond the preview

Go deeper on HAC2-431.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAC2-431.

Explore the full profile